Summary
Zoetis Inc. reported a solid performance for the second quarter and first half of 2019, demonstrating revenue growth driven by a combination of price increases, volume growth from in-line products (particularly dermatology), and contributions from the Abaxis acquisition. While overall net income saw a slight decline year-over-year for both periods, this was largely due to an unfavorable comparison with the prior year's tax benefits and the impact of new tax provisions like GILTI. Adjusted net income, which excludes certain non-recurring items and purchase accounting adjustments, showed robust growth, underscoring the underlying strength of the company's core operations. The company continues to expand its global reach, with both the U.S. and International segments contributing to revenue growth, although the International segment experienced an unfavorable foreign exchange impact. Investment in Research and Development remains strong, supporting future innovation. Management's proactive approach to managing foreign exchange risk and a healthy balance sheet, including ample cash reserves and undrawn credit facilities, position Zoetis favorably amidst a dynamic market.
Financial Highlights
54 data points| Revenue | $1.58B |
| Cost of Revenue | $479.00M |
| Gross Profit | $1.10B |
| SG&A Expenses | $391.00M |
| Operating Expenses | $1.05B |
| Interest Expense | $56.00M |
| Net Income | $433.00M |
| EPS (Basic) | $0.91 |
| EPS (Diluted) | $0.90 |
| Shares Outstanding (Basic) | 477.80M |
| Shares Outstanding (Diluted) | 481.50M |
Key Highlights
- 1Total revenue increased by 9% to $1.55 billion for the three months ended June 30, 2019, and by 8% to $3.00 billion for the six months ended June 30, 2019, compared to the prior year periods.
- 2Operational revenue growth, excluding foreign exchange impacts, was particularly strong at 14% for the quarter and 12% for the six months, driven by the Abaxis acquisition, price increases, and volume growth in key product lines.
- 3Net income attributable to Zoetis Inc. decreased by 3% to $371 million for the quarter and by 7% to $683 million for the six months, primarily due to unfavorable tax impacts compared to the prior year.
- 4Adjusted net income, a non-GAAP measure, demonstrated strong growth, increasing by 16% to $436 million for the quarter and by 16% to $860 million for the six months, indicating healthy underlying operational performance.
- 5The company reported an effective tax rate of 18.5% for the quarter and 18.3% for the six months, compared to 12.6% and 14.3% respectively in the prior year, largely due to tax law changes and the absence of significant prior-year tax benefits.
- 6Cash and cash equivalents increased to $1.76 billion as of June 30, 2019, from $1.60 billion as of December 31, 2018, supported by strong operating cash flows.
- 7The acquisition of Abaxis contributed significantly to revenue growth and was well-integrated, enhancing the company's diagnostics capabilities.